selected to act as standards (AA, AG, GG for each SNP).
1 5 0
Genotyping for the OPRM1 CAn dinucleotide repeat polymorphism, described in Kranzler et 7% and 14%, respectively. Alpha (two-tailed) was set to 0.5. If not otherwise stated, we report median and IQR. For The Spearman's method was employed to evaluate bivariate correlations and χ 2 tests with odds ratios over the 24-month period following study recruitment. In males, the AA genotype was significantly 1 9 6 associated with an elevated risk of alcohol-related hospital readmission (Males, readmitted: n(AA) = 1 9 7 62, n(AG/GG) = 14, non-readmitted: n(AA) = 21, n(AG/GG) = 16; females, readmitted: n(AA) = 38, 1 9 8 n(AG/GG) = 8, non-readmitted: n(AA) = 37, n(AG/GG) = 4; Fig. 1A ), higher median number of and genotype were investigated for associations with alcohol dependence or outcome in the NOAH 2 0 7 cohort. Mean CAn allele length did not significantly predict risk of alcohol dependence or alcohol- or days until first readmission (Spearman-Rho) in both the total group and the male and female subgroups. Similarly, no significant associations were observed between CAn genotype and alcohol 2 1 1 dependence or outcome (χ 2 tests, KWTs).
1 2
Promoter region SNPs rs3798677 (-73 bp relative to CAn) and rs3798678 (-3 bp relative to 2 1 3
CAn) had identical genotypes in the cohort (Tab. 1) and were also found to be in strong linkage 2 1 4 OPRM1, β -endorphin, and alcohol dependence 9 disequilibrium with A118G (rs3798677 AA/G-allele carriers vs. A118G AA/G-allele carriers; χ 2 = 2 1 5 8.287, p = 0.004). Similar to the CAn promoter variant, rs3798677 and rs3798678 did not significantly 2 1 6 predict dependence or outcome and were also not associated with the number of readmissions or days END concentrations declined significantly to a level that was also significantly lower than in control 2 2 4 subjects ( Fig. 2A ). Moreover, there was a significant negative correlation between withdrawal serum males (Spearman-Rho, n = 82, ρ = -0.097, p = 0.385). No significant associations between patient 2 2 7 serum β -END level and outcome were detected, except for one finding that day B β -END level was 2 2 8 correlated with days until first readmission in males (Spearman-Rho, n = 94, ρ = -0.232, p = 0.025). To test whether AA study subjects differ from G-allele carriers with regard to the effect of 2 3 2 prenatal sex hormone load on risk of alcohol dependence, we sex-and genotype-specifically interaction was observed in females ( Fig. 3B ). Subsequently, we explored whether similar interactions are also relevant to the patients' outcome. We previously reported a significant negative correlation from AA male patients with regard to the normalized 2D:4D values (Fig. 3C) , meaning a significantly 2 4 8 OPRM1, β -endorphin, and alcohol dependence 11 drinking days between AA individuals and G carriers, although the duration of their study (10 months) 2 7 1 was shorter than ours (24 months). Considering the G allele has been shown to strongly increase MOR Interestingly, we found that the A118G polymorphism does predict alcohol dependence in dietary fat preference (Lee et al., 2015) . Our findings in combination with these studies suggest 2 9 0 organizational sex hormone signaling may induce lasting changes to the endogenous opioid system 2 9 1 and mesolimbic reward pathway. The functional effects of the A118G polymorphism may explain how 2D:4D and OPRM1 2 9 3 A118G interact to influence alcohol dependence. Previously, the G-allele was shown to confer both 2 9 4 activational and inhibitory effects on mesolimbic reward signaling in that it increases receptor binding 2 9 5 affinity for β -END but also impairs OPRM1 transcription, making it an unreliable predictor of alcohol 2 9 6 dependence. However, after integrating 2D:4D values in our analyses, the G-allele becomes 2 9 7 significantly associated with elevated risk, as prenatal androgens have been shown to increase OPRM1 2 9 8
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OPRM1
, β -endorphin, and alcohol dependence 12 RNA expression irrespective of genotype and thus eliminate the protective, inhibitory effects of the G-2 9 9 allele on receptor expression (Huber et al., in press ). This 2D:4D-OPRM1 A118G interaction may also 3 0 0 explain why the G-allele tends to protect against dependence risk in our cohort of female study 3 0 1 subjects (OR = 1.91, p = 0.091) -females are exposed to far lower amounts of prenatal sex hormones 3 0 2 than males and therefore should retain the protective, inhibitory effects of the G-allele. Additional in 3 0 3 vitro and animal experiments will be required to establish the exact mechanism of the prenatal sex In addition to OPRM1 variation, we measured serum β -END level in healthy subjects and found peripheral β -END and brain β -END to be under independent regulation, so our serum 3 1 6 measurements may not accurately represent the effects of withdrawal on brain β -END processing withdrawal period. β -END level after longer withdrawal intervals may prove to be a stronger predictor 3 2 0 of long-term outcome. Interestingly, in a study completed by Racz et al. (2008) , female mice tended to be more OPRM1, β -endorphin, and alcohol dependence 13 endogenous opioid production and biological sex may converge on the HPA axis to influence 3 2 7 withdrawal-induced stress -an interaction that further highlights sex differences in the etiology of 3 2 8 alcohol dependence and outcome. Sex hormone signaling may also exert direct effects on β -END 3 2 9 production. A previous study from our group found that the number of CAGn repeats within exon 1 of withdrawal treatments, such as acamprosate, which has been found to both improve withdrawal There are several limitations to our approach. The associational study design prohibits us from readmitted to the hospital. We also have not corrected for multiple hypothesis testing. Furthermore, prenatal sex hormone load -the OPRM1 G-allele significantly predicts alcohol dependence and 3 4 8 outcome. Serum β -END level during withdrawal was also found to relate sex-specifically to outcome, as it correlates negatively with CIWA-Ar withdrawal severity in females but not in males. Since this 3 5 0 study is limited by its associational design, future work is needed to assess whether prenatal sex whether prenatal sex hormones and the opioid system are independent predictive factors of risk. manuscript, and approved the final version for publication. Schacht, J.P., Randall, P.K., Latham, P.K., Voronin, K.E., Book, S.W., Myrick, H., et al., 2017.
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